Prevalence and Clinical Impact of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolated From Hospitalized Patients

키워드

참고문헌 (40)

1. Klevens RM, "Invasive methicillin-resistant Staphylococcus aureus infections in the United States", JAMA, 298, pp.1763~1771 (2007)
2. Appelbaum PC, "The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus", Clin Microbiol Infect, 12(S1), pp.S16~S23 (2006)
3. Cui L, "Cell wall thickening is a common feature of vancomycin resistance in Staphylococcus aureus", J Clin Microbiol, 41, pp.5~14 (2003)
4. Hiramatsu K, "Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance", Lancet Infect Dis, 1, pp.147~155 (2001)
5. Hiramatsu K, "Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility", J Antimicrob Chemother, 40, pp.135~136 (1997)
6. Hiramatsu K, "Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin", Lancet, 350, pp.1670~1673 (1997)
7. Sieradzki K, "The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection", N Engl J Med, 340, pp.517~523 (1999)
8. Smith TL, "Emergence of vancomycin resistance in Staphylococcus aureus", N Engl J Med, 340, pp.493~501 (1999)
9. Kim MN, "Vancomycin-intermediate Staphylococcus aureus in Korea", J Clin Microbiol, 38, pp.3879~3881 (2000)
10. Kim MN, "Clonal spread of Staphylococcus aureus heterogeneously resistant to vancomycin in a university hospital in Korea", J Clin Microbiol, 40, pp.1376~1380 (2002)
11. Song JH, "Emergence in Asian countries of Staphylococcus aureus with reduced susceptibility to vancomycin", Antimicrob Agents Chemother, 48, pp.4926~4928 (2004)
12. Park KH, "Comparison of the clinical features, bacterial genotypes and outcomes of patients with bacteremia due to heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-susceptible S. aurues", J Antimicrob Chemother, 67, pp.1843~1849 (2012)
13. Wootton M, "A modified population analysis profile (PAP) method to detect hetero-resistance to vancomycin in Staphylococcus aureus in a UK hospital", J Antimicrob Chemother, 47, pp.399~403 (2001)
14. Howden BP, "Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications", Clin Microbiol Rev, 23, pp.99~139 (2010)
15. Yusof A, "Evaluation of a new E test vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA", J Clin Microbiol, 46, pp.3042~3047 (2008)
16. Leonard SN, "Evaluation of the E test GRD for the detection of Staphylococcus aureus with reduced susceptibility to glycopeptides", J Antimicrob Chemother, 63, pp.489~492 (2009)
17. Satola SW, "Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method", J Clin Microbiol, 49, pp.177~183 (2011)
18. Charles PG, "Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus", Clin Infect Dis, 38, pp.448~451 (2004)
19. Musta AC, "Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years", J Clin Microbiol, 47, pp.1640~1644 (2009)
20. Horne KC, "Prospective comparison of the clinical impacts of heterogeneous vancomycin-intermediate methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-susceptible MRSA", Antimicrob Agents Chemother, 53, pp.3447~3452 (2009)
21. Maor Y, "Prevalence and characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a tertiary care center", J Clin Microbiol, 45, pp.1511~1514 (2007)
22. Fong RK, "Clinical features and treatment outcomes of vancomycin-intermediate Staphylococcus aureus (VISA) and heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) in a tertiary care institution in Singapore", Eur J Clin Microbiol Infect Dis, 28, pp.983~987 (2009)
23. Bae IG, "Heterogeneous vancomycin-intermediate susceptibility phenotype in bloodstream methicillin-resistant Staphylococcus aureus isolates from an international cohort of patients with infective endocarditis: prevalence, genotype, and clinical significance", J Infect Dis, 200, pp.1355~1366 (2009)
24. Neoh HM, "Impact of reduced vancomycin susceptibility on the therapeutic outcome of MRSA bloodstream infections", Ann Clin Microbiol Antimicrob, 6, pp.13~ (2007)
25. CLSI, "Performance standards for antimicrobial susceptibility testing. Twenty-fifth Informational supplement", Clinical and Laboratory Standards Institute, ~ (2015)
26. Levy MM, "2001 SCCM", ESICM, ATS, pp.SIS International Sepsis Definitions Conference, Crit Care Med[DOI]
27. Guilarde AO, "Staphylococcus aureus bacteraemia: incidence, risk factors and predictors for death in a Brazilian teaching hospital", J Hosp Infect, 63, pp.330~336 (2006)
28. Durack DT, "New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service", Am J Med, 96, pp.200~209 (1994)
29. Harbarth S, "Impact of methicillin resistance on the outcome of patients with bacteremia caused by Staphylococcus aureus", Arch Intern Med, 158, pp.182~189 (1998)
30. Lew DP, "Osteomyelitis", Lancet, 364, pp.369~379 (2004)
31. Mylotte JM, "Staphylococcus aureus bacteremia: predictors of 30-day mortality in a large cohort", Clin Infect Dis, 31, pp.1170~1174 (2000)
32. Horan TC, "CDC definitions of nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical wound infections", Infect Control Hosp Epidemiol, 13, pp.606~608 (1992)
33. González C, "Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms", Clin Infect Dis, 29, pp.1171~1177 (1999)
34. Kumar M, "Persistent pneumonia: Underlying cause and outcome", Indian J Pediatr, 76, pp.1223~1226 (2009)
35. Rybak MJ, "Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007)", J Clin Microbiol, 46, pp.2950~2954 (2008)
36. van Hal SJ, "Systemic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates", Antimicrob Agents Chemother, 55, pp.405~410 (2011)
37. Liu C, "Staphylococcus aureus with heterogeneous resistance to vancomycin: epidemiology, clinical significance, and critical assessment of diagnostic methods", Antimicrob Agents Chemother, 47, pp.3040~3045 (2003)
38. Sieradzki K, "Alterations of cell wall structure and metabolism accompany reduced susceptibility to vancomycin in an isogenic series of clinical isolates of Staphylococcus aureus", J Bacteriol, 185, pp.7103~7110 (2003)
39. Kullar R, "Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets", Clin Infect Dis, 52, pp.975~981 (2011)
40. Howden BP, "Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility", Clin Infect Dis, 38, pp.521~528 (2004)

관련 논문AI추천